

REDX PHARMA PLC
("Redx" or "the Company")

Appointment of Non-Executive Director

Alderley Park, 19 May 2021 Redx Pharma (AIM:REDX), the drug discovery and development company focused on oncology and fibrosis, is pleased to announce the appointment of Natalie Berner as a Non-Executive Director with effect from 19 May 2021. Natalie will represent RM Special Holdings 3 LLP, an affiliate of Redmile Group, LLC, a San Francisco based investment firm that focuses on the health care sector ("Redmile"), on the Board of Directors.

Natalie brings extensive experience in the healthcare sector to the Board. She is a Managing Director focusing on Therapeutics at Redmile, which she joined in 2016. Prior to Redmile, Natalie was a Research Associate at the New York University School of Medicine. Natalie received a BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University.

Iain Ross, Chairman of the Board of Redx commented: *"We are delighted to welcome Natalie onto the Redx Board to represent Redmile, one of the Company's key investors who have been instrumental in helping us to raise the funds to successfully execute on our business plans. The Board and I look forward to working with Natalie to ensure that we continue to grow Redx into a successful biotech company focused on the treatment of cancer and fibrotic disease."*

Following Natalie's appointment, the board will be comprised of seven directors, four of whom including the Chairman are Independent Non-executive Directors (Iain Ross, Peter Presland, Dr Bernhard Kirschbaum and Sarah Gordon Wild), two shareholder representative non-executive Directors (Natalie Berner and Dr Thomas Burt) and Lisa Anson as Chief Executive.

Additional information:

The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies:

Full name and age: Natalie Brittenham Berner, aged 30

Ms. Berner does not hold any shares in the Company

Ms. Berner is not currently a director of any company and has not been a director of any company in the past five years

For further information, please contact:

Redx Pharma Plc

Iain Ross, Chairman

Lisa Anson, Chief Executive

T: +44 1625 469 918

SPARK Advisory Partners Limited (Nominated Advisor)

Matt Davis/Adam Dawes

T: +44 20 3368 3550

WG Partners LLP (Joint Broker)

Claes Spång/ David Wilson

T: +44 20 3705 9330**Panmure Gordon (UK) Limited (Joint Broker)**

Rupert Dearden/Freddy Crossley/Emma Earl

T: +44 20 7886 2500**FTI Consulting**

Simon Conway/Ciara Martin

T: +44 20 3727 1000**About Redx Pharma Plc**

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in mid-2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).